Skip to main content
. Author manuscript; available in PMC: 2016 Oct 24.
Published in final edited form as: Leuk Lymphoma. 2014 Nov 19;56(7):1938–1948. doi: 10.3109/10428194.2014.974594

Figure 7.

Figure 7

Cumulative incidence of deep molecular response (MR 4.5) dependent on BCR – ABL1 transcript levels at 3, 6, 12 and 18 months. The fastest and highest level of MR 4.5 is achieved in patients who have achieved a major molecular response (MMR, <0.1% IS) at the respective time points.